Drug Trial Radar · NCT00433017
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
Last checked: Nov 19, 2026Latest source record: Apr 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
255
Actual
Start
May 2007
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 9, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration
Conditions
- Macular Degeneration
- Choroidal Neovascularization
Interventions
Verteporfin Photodynamic TherapyDrug
After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of the infusion.
RanibizumabDrug
Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
PlaceboDrug
As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-corrected Visual Acuity (BCVA) at Month 12.Time frame: Baseline and Month 12
- Percent of Participants With a Treatment-free Interval of at Least 3 Months Following the Month 2 VisitTime frame: Month 2 to Month 11
Locations
12 sites in 12 countries. Site status is shown where the registry gives one.
Novartis Investigative site
Vienna, Austria
Novartis Investigative site
Antwerp, Belgium
Novartis Investigative site
Aalborg, Denmark
Novartis Investigative site
Créteil, France
Novartis Investigative site
Regensburg, Germany
Novartis Investigative site
Budapest, Hungary
Novartis Investigative site
Florence, Italy
Novartis Investigative site
Rotterdam, Netherlands
Novartis Investigative site
Warsaw, Poland
Novartis Investigative site
Madrid, Spain
Novartis Investigative site
Geneva, Switzerland
Novartis Investigative site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.